Epigenetic therapy using DNA methylation inhibitors and histone deacetylase (HDAC) inhibitors has clinical promise for the treatment of human malignancies. To investigate roles of microRNAs (miRNAs) on epigenetic therapy of gastric cancer, the miRNA expression profile was analysed in human gastric cancer cells treated with 5-aza-2 0 -deoxycytidine (5-Aza-CdR) and 4-phenylbutyric acid (PBA). miRNA microarray analysis shows that most of miRNAs activated by 5-Aza-CdR and PBA in gastric cancer cells are located at Alu repeats on chromosome 19. Analyses of chromatin modification show that DNA demethylation and HDAC inhibition at Alu repeats activates silenced miR-512-5p by RNA polymerase II. In addition, activation of miR-512-5p by epigenetic treatment induces suppression of Mcl-1, resulting in apoptosis of gastric cancer cells. These results suggest that chromatin remodeling at Alu repeats plays critical roles in the regulation of miRNA expression and that epigenetic activation of silenced Alu-associated miRNAs could be a novel therapeutic approach for gastric cancer.
Introduction
Chromatin-modifying drugs such as DNA methylation inhibitors and histone deacetylase (HDAC) inhibitors are emerging as effective agents for 'epigenetic therapy' of cancer (Yoo and Jones, 2006; Gal-Yam et al., 2008) . In fact, the DNA methylation inhibitors 5-aza-2 0 -deoxycytidine (5-Aza-CdR) and 5-azacytidine (5-Aza-CR) were recently approved by the Food and Drug Administration for the treatment of myelodysplastic syndrome, and many HDAC inhibitors such as 4-phenylbutyric acid (PBA) are under clinical trials (Yoo and Jones, 2006) . However, the molecular mechanisms underlying anticancer effect of these drugs are not fully understood.
MicroRNAs (miRNAs) are small non-coding RNAs, which can downregulate various target genes. miRNAs are expressed in a tissue-specific manner and have important functions in cellular proliferation, apoptosis and differentiation. Recent studies have indicated that aberrant expression of miRNAs contributes to the initiation and progression of human malignancies (Calin and Croce, 2006a, b) . We have recently shown that some miRNAs are located near CpG islands and that expression of these miRNAs is regulated by alterations in DNA methylation and histone modification on their CpG islands (Saito and Jones, 2006; .
As the stomach is an organ in which epigenetic alterations due to Helicobacter pylori infection or various exogenous antigen exposures are frequently observed (Esteller, 2002) , we are prompted to investigate miRNA expression profile in gastric cancer cells with epigenetic treatment. Interestingly, microarray analysis of AGS gastric cancer cells shows that most of the miRNAs, which are dramatically activated by 5-AzaCdR and PBA, are located at Alu repeats on chromosome 19. Alu elements are B280 bp in length and consist of two similar, but distinct, monomers linked by an oligo (dA) tract. It has been reported that Alu repeats in the miRNA cluster on chromosome 19 can function as RNA polymerase III (Pol III) promoters of miRNAs (Borchert et al., 2006) . Here we show that chromatin remodeling at Alu repeats by DNA demethylation and HDAC inhibition can activate expression of Aluassociated miRNAs, which can downregulate target oncogenes in human gastric cancer cells.
Results miRNAs activated by epigenetic treatment in gastric cancer cells are located at Alu repeats on chromosome 19 To identify miRNAs, which are regulated by DNA demethylation and HDAC inhibition, we carried out miRNA microarray analysis. The miRNA expression profile of AGS human gastric cancer cells showed that 115 out of 470 miRNAs were differentially expressed by the treatment with 5-Aza-CdR and PBA (Po0.01).
Interestingly, 14 out of top 15 miRNAs (93%) upregulated by epigenetic treatment are located in the miRNA cluster on chromosome 19 (Figure 1a ) (Bentwich et al., 2005) . These miRNAs are interspersed among Alu repeats which can function as their promoters (Borchert et al., 2006) . We have recently reported that epigenetic treatment of T24 bladder cancer cells induced activation of only 5 Alu-associated miRNAs in top 15 miRNAs (33%) (Figure 1a ) . In addition, the signal ratios of Aluassociated miRNAs after epigenetic treatment in AGS cells compared with untreated cells were much higher than those in T24 cells. Therefore, activation of Aluassociated miRNAs by DNA demethylation and HDAC inhibition seems to be more specific in gastric cancer cells compared with bladder cancer cells.
To confirm the miRNA microarray data, we carried out quantitative reverse transcriptase (RT)-PCR analyses for miR-512-5p, -517b, -526b, -518b and -515-5p in AGS cells treated with 5-Aza-CdR and PBA. As shown in Figure 1b , all miRNAs examined were silenced before treatment and dramatically activated by 5-Aza-CdR and PBA treatment, which is consistent with the microarray data. Other gastric cancer cell lines (TMK1 and MKN45) also showed marked upregulation of miR-512-5p and miR-517b by epigenetic treatment (Figure 1c ).
DNA demethylation and HDAC inhibition at Alu repeats activates silenced miR-512-5p As epigenetic treatment remarkably upregulate expression of Alu-associated miRNAs, we examined DNA methylation and histone modification at the Alu promoter region of miR-512 by bisulfite genomic sequencing and chromatin immunoprecipitation (ChIP) assay, respectively (Figures 2a and b) . It was found that although the Alu promoter regions of miR-512 were completely methylated (100%) in untreated AGS cells, DNA methylation levels were reduced to 20% after epigenetic treatment (Figure 2a) .
Both acetylated histone H3 and methylated histone H3-lysine 4 (K4) are associated with an open chromatin structure and active gene expression. Significant increases in the levels of both acetylated histone H3 and methylated histone H3-K4 were found at the Alu promoter region of miR-512 in AGS cells treated with 5-Aza-CdR and PBA (Figure 2b ). These findings indicate that dense DNA methylation and closed chromatin structure at Alu repeats are associated with a silent state of miR-512-5p, and that chromatin remodeling at Alu repeats by DNA demethylation and HDAC inhibition activate silenced miR-512-5p. 
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Activation of miR-512-5p by epigenetic treatment is mediated by Pol II To assess whether epigenetic activation of miR-512-5p is mediated by Pol II or Pol III, we have carried out ChIP assay of Pol II and Pol III on the promoter region of miR-512-5p in AGS cells (Figure 3a) . The results of ChIP assay show that Pol II signal at Alu repeats is significantly increased after epigenetic treatment, whereas Pol III signal shows no increase. Pol II is highly sensitive to a-amanitin and therefore treatment of 
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Y Saito et al mammalian cells with a-amanitin at a concentration of 50 mg/ml for 5-9 h results in the selective inhibition of Pol II. AGS cells with epigenetic treatment were incubated in 0 or 50 mg/ml of a-amanitin for 7 h before the cells were harvested for assay. As shown in Figure 3b , we have found that the epigenetic activation of miR-512-5p is inhibited by a-amanitin treatment.
In addition, we have identified the putative Pol II transcriptional start site of miR-512-5p by 5 0 -rapid amplification of cDNA ends (5 0 -RACE) (Figure 2a ). These findings indicate that activation of miR-512-5p by epigenetic treatment is mediated by Pol II.
Overexpression of miR-512-5p suppresses Mcl-1 and induces apoptosis Identification of target genes of Alu-associated miRNAs is essential to investigate their biological function. Recent studies have shown that miRNAs can regulate expression of their target genes by decreasing mRNA stability, in addition to translational inhibition (Yekta et al., 2004; Bagga et al., 2005; Wu et al., 2006) . The strategy to identify target genes of miR-512-5p is shown in Figure 4a . First of all, we conducted a microarray analysis to screen for genes that were threefold downregulated by treatment with 5-Aza-CdR and PBA, because target genes of miR-512-5p were expected to be suppressed by overexpression of miR-512-5p. Then, we identified 69 genes, which are known to be involved in cell proliferation, apoptosis and differentiation. We finally selected nine genes as potential target genes of miR-512-5p by referring to the database for the prediction of miRNA targets (microRNA.org, http:// www.microrna.org). Among these nine genes, we especially focused on well-known oncogenes, Jun and Mcl-1. To confirm that Jun and Mcl-1 are target genes of miR-512-5p, AGS cells were transfected with miR-512-5p precursor molecules, and the expression levels of Jun and Mcl-1 were assessed by quantitative RT-PCR. As shown in Figure 4b Epigenetic activation of miR-512-5p Y Saito et al treatment with 5-Aza-CdR and PBA and after transfection of miR-512-5p (Figure 4c ).
In addition, levels of apoptosis were evaluated by photometric enzyme-immunoassay for the detection of cytoplasmic histone-associated DNA fragments. Significant increase of the levels of cytoplasmic histoneassociated DNA fragments (mono-and oligonucleosomes) was observed in AGS cells both after treatment with 5-Aza-CdR and PBA and after transfection of miR-512-5p (Figure 4d) .
To further confirm target specificity between miR-512-5p and its potential target, Mcl-1, we carried out luciferase reporter assay with a vector containing the putative Mcl-1 3 0 untranslated region (UTR) target site downstream of the luciferase reporter gene, which was transfected into AGS cells. Base pairing between miR-512-5p and wild-type (WT) or mutant (MUT) target site in the 3 0 UTR of Mcl-1 mRNA is shown in Figure 5a . Luciferase activities of AGS cells transfected with Mcl-1-WT construct were significantly lower after epigenetic treatment and after transfection of miR-512-5p, whereas those with Mcl-1-MUT construct showed no significant difference (Figure 5b ). These data suggest that Mcl-1 is one of the targets of miR-512-5p and that activation of miR-512-5p induces suppression of Mcl-1, resulting in apoptosis of gastric cancer cells.
Discussion
Alu repeats are the most frequent repetitive elements in the human genome and have been considered as 'junk DNA' with no important function. However, Borchert et al. (2006) have shown that Alu repeats in the miRNA cluster on chromosome 19 can function as Pol III promoters of downstream miRNAs. These Alu-associated miRNAs are shown to be silenced in the human tissues except the placenta (Bentwich et al., 2005) . We also found that Alu-associated miRNAs are silenced in both gastric cancers and non-cancerous mucosae (data not shown).
In this study, we show that one of the Alu-associated miRNAs, miR-512-5p, is silenced by epigenetic mechanisms, and that chromatin remodeling at Alu repeats by DNA methylation inhibitors and HDAC inhibitors can activate expression of silenced miR-512-5p in human gastric cancer cells. The DNA demethylating agent 5-Aza-CdR and HDAC inhibitor PBA were effective at reducing DNA methylation level and activating chromatin structure at the promoter region of miR-512-5p. In agreement with our results, earlier studies have suggested that Alu transcription is regulated by epigenetic mechanisms such as DNA methylation and histone modification at Alu repeats (Liu et al., 1994; Kondo and Issa, 2003) .
Although it has been reported that Alu-associated miRNAs are transcribed by Pol III (Borchert et al., 2006) , our results suggest that epigenetic activation of miR-512-5p is mediated by Pol II. Interestingly, Alu elements on the promoter region of miR-512-5p are separated from mature miR-512-5p sequences by Pol III terminator (TTTT), indicating that Pol III at Alu elements cannot transcribe miR-512-5p (Figure 2a ). This finding supports our results that chromatin remodeling by epigenetic treatment at Alu repeats can activate miR-512-5p through Pol II. A recent study also reports about Pol II transcription associated with Alu repeats and CpG islands in human promoters (Oei et al., 2004) .
Gastric cancer is the second most common cause of cancer-related death worldwide. Although the incidence of gastric cancer has declined in western countries, it remains a major health problem throughout the rest of the world, especially in China and Japan (Parkin, 2001) . 
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For gastric cancer that is diagnosed at an advanced stage, systemic chemotherapy is the only treatment available, besides supportive care. The Mcl-1 gene is a member of the Bcl-2 family and an anti-apoptotic protein originally isolated from the ML-1 human myeloid leukemia cell line during cell differentiation (Kozopas et al., 1993) . The biological relevance of Mcl-1 as an anti-apoptotic protein promoting cell survival has been reported in various human malignancies (Zhou et al., 1997; Shigemasa et al., 2002; Taniai et al., 2004) . Elevated expression of Mcl-1 and its association with poor prognosis have been reported in gastric cancer (Krajewska et al., 1996; Maeta et al., 2004) . Interestingly, Wacheck et al. (2006) have proposed Mcl-1 antisense therapy as a promising approach for the treatment of gastric cancer. They have shown that downregulation of Mcl-1 by antisense therapy produced a significant increase in apoptosis and a decrease in cell growth, and that the combination of Mcl-1 antisense oligonucleotide and anti-cancer agents, such as docetaxel and cisplatin, showed synergistic chemopreventive activity (Wacheck et al., 2006; Zangemeister-Wittke and Huwiler, 2006) . Our results show that activation of miR-512-5p induced by chromatin-modifying drugs suppresses Mcl-1, resulting in apoptosis of gastric cancer cells. In addition, activation of Alu-associated miRNAs by epigenetic treatment seems to be more specific in gastric cancer cells compared with bladder cancer cells. These results indicate that Alu-associated miRNAs could be novel therapeutic targets of human gastric cancer.
In conclusion, our results suggest that chromatin remodeling at Alu repeats by DNA demethylation and HDAC inhibition can induce expression of silenced miRNAs, which can serve as 'endogenous silencers' of target oncogenes in gastric cancer cells. As there is a possibility that other proteins activated by epigenetic treatment may also contribute to apoptosis in gastric cancer cells, further studies are necessary to verify whether activation of Alu-associated miRNAs by epigenetic therapy could be an effective approach for the prevention and treatment of human gastric cancer.
Materials and methods

Cell lines and epigenetic treatment
The AGS, MKN45 and TMK1 human gastric cancer cell lines were used. AGS was obtained from the American Type Culture Collection (Rockville, MD, USA), and MNK45 was obtained from the Japan Health Science Foundation (Osaka, Japan). TMK1 is a generous gift from Dr Wataru Yasui (Ochiai et al., 1985) . Cells were cultured in RPMI1640 medium supplemented with 10% fetal bovine serum. They were seeded at 24 h before treatment with 5-Aza-CdR (Sigma-Aldrich, St Louis, MO, USA) and PBA (Sigma-Aldrich). 5-Aza-CdR was removed after 24 h, whereas the cells were continuously exposed to PBA for 96 h.
RNA extraction and microarray analyses
Total RNA, including small RNA, was extracted using the mirVana miRNA isolation kit (Ambion, Austin, TX, USA). miRNA microarray analysis was carried out by LC Sciences (www.lcsciences.com, Houston, TX, USA), and gene expression profile was analysed using the whole human genome oligo microarray kit (Agilent technologies, Santa Clara, CA, USA). All data were submitted to the ArrayExpress database, and the accession numbers are E-MEXP-1820 and E-MEXP-1821, respectively.
Quantitative RT-PCR of miRNAs MicroRNA expression levels were analysed by quantitative RT-PCR using the TaqMan microRNA assay for miR-512-5p, -515-5p, -517b, -518b and -526b (Applied Biosystems, Foster City, CA, USA), in accordance with the manufacturer's instructions.
Bisulfite genomic sequencing Genomic DNA was converted with sodium bisulfite. After amplification of the bisulfite-converted DNA by nested PCR with specific primers for miR-512, DNA methylation levels were analysed by bisulfite genomic sequencing as described earlier . The sequences of the primers used are listed in Supplementary Table 1 .
Chromatin immunoprecipitation assay
The ChIP assay was carried out as described earlier . Antibodies to dimethylated histone H3-K4 (Upstate, Temecula, CA, USA), acetylated histone H3 (Upstate), Pol II (Upstate) and Pol III (anti-RPC 53, see Acknowledgements) were used. Quantitative analysis was carried out by real-time PCR with the CYBR Premix Ex Taq (Takara Bio, Ohtsu, Japan) using the Thermal Cycler Dice Real-Time System (Takara Bio). The sequences of the primers used are listed in Supplementary Table 1. The fraction of immunoprecipitated DNA was calculated as follows: (immunoprecipitated DNA with each antibodyÀnonspecific antibody control (NAC))/(input DNAÀNAC).
5
0 -Rapid amplification of cDNA ends 5 0 ends of mRNA were detected using the RLM-RACE kit (Ambion) according to the manufacturer's protocols. The inner 5 0 RLM-RACE PCR products were cut from 2% agarose gel, purified using Gel Extraction Kit (Qiagen, Tokyo, Japan) and sequenced with an inner gene-specific primer. The sequences of the primers used are listed in Supplementary Table 1 .
Western blotting and quantitative RT-PCR Protein extracts were separated by SDS/polyacrylamide gel electrophoresis and transferred onto a nitrocellulose membrane. Membranes were hybridized with antibodies against Mcl-1 (S-19, Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Total RNA was used for reverse transcription. After incubation with DNase I (Promega, Madison, WI, USA) to eliminate DNA contamination, Superscript III (Invitrogen, Carlsbad, CA, USA) and random hexamers (Invitrogen) were added for first-strand cDNA synthesis, then, quantitative PCR was carried out with primers specific for Jun and Mcl-1 (Supplementary Table 1 ).
Transfection of miR-512-5p precursor molecules
The miR-512-5p precursor molecules and negative control 1 precursor miRNAs were purchased from Ambion. They were transfected into AGS cells at a final concentration of 100 nM each using oligofectamine (Invitrogen), in accordance with the manufacturer's instructions. At 48 h after transfection, cells were collected and the expression of Mcl-1 was analysed by western blotting as described above.
Apoptosis assay AGS cells were transfected with miR-512-5p and negative control or treated with 5-Aza-CdR and PBA. Forty-eight hours later, apoptosis was evaluated by photometric enzymeimmunoassay for the detection of cytoplasmic histoneassociated DNA fragments using the Cell Death Detection ELISA kit (Roche, Mannheim, Germany) (Suzuki et al., 1998) .
Luciferase assay
Luciferase constructs were made by ligating oligonucleotides containing the wild-type or mutant target site of the Mcl-1 3 0 UTR into the Xba I site of the pGL3-control vector (Promega, Figure 5a ). AGS cells were transfected with 0.4 mg of firefly luciferase reporter vector containing wild-type or mutant target site and 0.02 mg of the control vector containing Renilla luciferase, pRL-CMV (Promega), using lipofectamine 2000 (Invitrogen) in 24-well plates. Luciferase assays were carried out at 48 h after transfection using the Dual Luciferase Reporter Assay System (Promega). Firefly luciferase activity was normalized to Renilla luciferase activity.
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